BSEGeneral3h ago · 18 Nov 2026, 07:03 pm
Outcome of Board Meeting pursuant to Regulation 30 of SEBI LODR, 2015 to consider and approve of financial restructuring , exploring strategic options and convening of EGM of the Company
Mangalam Drugs & Organics Ltd · 532637
✦ AI SummaryResults
Mangalam Drugs & Organics Ltd's board approved financial restructuring, exploring strategic options, and convening an EGM to seek approval for the proposed sale/disposal of its leasehold land rights and building. The proposal is at an exploratory stage, and no definitive agreement has been entered into. The expected date of completion is uncertain and will depend on identifying a suitable buyer, finalizing commercial terms, and obtaining requisite approvals.
Analysis Scores
Earnings Impact5/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk6/10
Balance Sheet Risk8/10
Liquidity Impact5/10
Market Sentiment4/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Mangalam Drugs & Organics Ltd - 532637 - Board Meeting Outcome for Outcome Of Board Meeting Pursuant To Regulation 30 Of SEBI LODR, 2015
Attachments (1)
📄pdf
Download →
235973e2-7b5a-47d2-be65-01e7ff305a54.pdf
View document text
Mangalam Drugs and Organics Limited
Regd. Office : Rupam Building, 3rd Floor, 239 P. D’'Mello Road, NearG. P. O. Mumbai - 400 001
@ 91-22-62616200 / 6300 / 8787 @ 91-22-€ 2619090 o CIN : L24230MH1972PLC116413
REF: MDOL/CS-SE/2026-27/045 November 18", 2026
Listing Department Listing Department
BSE Ltd
National Stock Exchange of India
1* Floor, New Trade Wing, Limited
Phiroze Jecjeebhoy Towers, “Exchange Plaza”, 5" Floor,
Dalal Street, Fort, Plot No. C-1, Block G,
Mumbai — 400 001 Bandra - Kurla Complex,
Bandra(E), Mumbai — 400 051
Serip Code: 532637
Symbol: MANGALAM
Subject: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure
Requirements) Regulations, 2015 —Proposal for Sale of Company’s undertaking.
Dear Sir/Madam,
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements)
Regulations, 2015 read with Part A of Schedule 111 thereto, and the SEBI Master Circular No.
HO/49/14/14(7)2025-CFD-POD2/1/3762/2026 dated January 30, 2026 (Chapter V, Section V-
A, read with Annexure 18 and Annexure 18A thereto), we wish to inform you that the Board
of Directors of the Company, at its meeting held on Wednesday, 18" November, 2026,
considered and approved the proposal for undertaking financial restructuring and exploring
various strategic options for the Company, including the potential sale/disposal of the
Company's leasehold land rights and building situated at Unit-2, Plot No. 1203, GIDC, Vapi,
District Valsad, Gujarat —396195.
In this regard, the Board has also approved convening the Extra-Ordinary General Meeting
(EGM) of the Members of the Company for the financial year 2026-27 to scek their approval,
wherever required under applicable laws, in respect of the proposed strategic options and to
authorise the Board of Directors to take all necessary steps and actions in this regard.
It is clarified that the proposal is presently at an exploratory stage and the Company has not
entered into any definitive agreement or arrangement for the proposed sale/disposal. The
identity of the prospective buyer(s), consideration, commercial terms and other transaction-
related particulars shall be determined at an appropriate stage, subject to necessary approvals
and compliance with applicable laws
The relevant disclosures in respect of the proposed sale/disposal of the aforesaid undertaking,
in accordance with Regulation 30 of the SEBI Listing Regulations, are enclosed herewith as
Annexure-1.
Factory : at Vapi (Gujarat) India ® cont ctus@mangalamdrugs.com @ http://www.mangalamdrugs.com
Mangalam Drugs and Organics Limited %
MANGALAM
Regd: Office : Rupam Building, 3rd Floor, 239 P. D’Mello Road, Near G. P. . Mumbai - 400 001 -’
® 91-22-62/6 613060 2/ 807807 @ 91-22-62619090 » CIN : 124230MH1972PLC116413 wHoe
The aforesaid information shall also be made available on the Company's website at
www.mangalamdrugs.com.
The Meeting of the board of Directors of the Company commenced at 02:30 p.m. and concluded
at 05:00 p.m.
Kindly take the same on record. Thanking you,
For Mangalam Drugs and Organics Limited
Govardhan Murlidhar Dhoot
Managing Director
DIN: 01240086
Factory : at Vapi (Gujarat) India ® contactus@mangalamdrugs.com @ http://www.mangalamdrugs.com
Mangalam Drugs and Organics Limited
MANGALAM
Hvrd Office : Rupam Building, 3rdF\ oor 239 P. D' M(“O R( ad, Near G. P. 0. Mumbai - 400 001
@ 91-22-62/ 663010 6/ 827807 0@ 9 1- 22-62619090o CIN : L24230MH1972PLC116413
ANNEXURE-1
CONTINUOUS DISCLOSURE UNDER SUB-PARA 1 OF PARA A OF PART A OF
SCHEDULE I PURSUANT TO REGULATION 30 OF THE SEBI (LODR)
REGULATION, 2015
Particulars of the proposed sale/disposal of leasehold land rights and building situated at
Unit-2, Plot No. 1203, GIDC, Vapi, District Valsad, Gujarat — 396195
]i:;' Particulars Details
1 | The amount and || Sr no | Particulars Amount %
percentage of the turnover Rsin
or revenue or income and || er
net worth contributed by ||1 . Revenue/Turnover 74.46 cr 32%
such unit or division or ||2 . Total Income T446cr [32%
undertaking or subsidiary || 3. Net worth = -
or associate company of
the listed entity during the [The Revenue / Total Income of listed Entity is 232.90cr.
last financial year;
2 Date on which the | Not Applicable at this stage, as the proposal is presently at
agreement for sale has | an exploratory stage and no definitive agreement for
been entered into; ‘ sale/disposal has been entered into by the Company.
3 The expected date | The expected date of completion of the proposed
of completion of sale/disposal is presently not ascertainable and shall depend
| sale/disposal: upon the identification of a suitable prospective buyer,
| finalisation of commercial terms and receipt of requisite
statutory, regulatory and shareholders' approvals, wherever
applicable.
i Consideration The consideration receivable, if any, has not yet been
received/receivable from | determined, as the proposal is at an exploratory stage and
such sale/ disposal; no valuation or definitive commercial terms have been
finalized.
5 Brief details of buycr(s)fi Not Applicable at this stage, as no prospective buyer has
and whether the buyers | been identified or finalised by the Company. The requisite
belongs to the | details shall be disclosed upon identification and
promoter/promoter finalisation of the prospective buyer, in accordance with
group/group companies. If | applicable regulatory requirements.
yes, details thereof;
Factory : at Vapi (Gujarat) India @ contactus@mangalamdrugs.com @ http;//www.mangalamdrugs.com
Mangalam Drugs and Organics Limited
f Regd. Office : Rupam Building, 3rd Floor, 239 P. D’M(:Ho‘Rmd, Near G. P. 0. Mumbai - 400 001
® 91-22-62616200 / 63/0 87087 & 91-22-62619090 CIN : L24230MH1972PLC116413 | Accredited
Whether the transaction The applicability of related party transaction provisions
would fall within related shall be examined upon identification of the prospective
party transactions? If yes, buyer and finalisation of the proposed transaction. If the
whether the same is done proposed transaction constitutes a Related Party
at “arm’s length™; Transaction, the same shall be undertaken subject to the
requisite approvals and compliance with applicable
provisions of the Companies Act, 2013 and SEBI Listing
Regulations, including the requirement of being on an arm's
length basis, wherever applicable.
Whether the sale, lease or The proposed sale/disposal is presently being explored
disposal oft he undertaking independently and is not contemplated as part of any
is outside Scheme of Scheme of Arrangement. The applicability of Regulation
Arrangement? If yes, 37A of the SEBI Listing Regulations and other applicable
details of the same provisions shall be examined based on the final structure
including compliance with and terms of the proposed transaction. The Company shall
regulation 37A of LODR obtain the requisite shareholders' approval and comply with
Regulations. all applicable regulatory requirements, including
Regulation 37A, wherever applicable, before undertaking
the proposed sale/disposal
Additionally. in case of a Not Applicable at this stage, as the proposal is presently at
slump sale, indicative an exploratory stage and no decision has been taken
disclosures provided for regarding the structure or mode of the proposed transaction,
amalgamation/merger, including whether the same would be undertaken by way of
shall be disclosed by the a slump sale.
listed entity with respect to
such slump sale.
For Mangalam Drugs and Organics Limited
Govardhan Murlidhar Dhoot
Managing Director
DIN: 01240086
Factory : at Vapi (Gujarat) India @ contactus@mangalamdrugs.com @ http://www.mangalamdrugs.com